A citation-based method for searching scientific literature

Yves Pommier, Mark J O'Connor, Johann de Bono. Sci Transl Med 2016
Times Cited: 283



Arnab Ray Chaudhuri, Elsa Callen, Xia Ding, Ewa Gogola, Alexandra A Duarte, Ji-Eun Lee, Nancy Wong, Vanessa Lafarga, Jennifer A Calvo, Nicholas J Panzarino, Sam John, Amanda Day, Anna Vidal Crespo, Binghui Shen, Linda M Starnes, Julian R de Ruiter, Jeremy A Daniel, Panagiotis A Konstantinopoulos, David Cortez, Sharon B Cantor, Oscar Fernandez-Capetillo, Kai Ge, Jos Jonkers, Sven Rottenberg, Shyam K Sharan, André Nussenzweig. Nature 2016
Times Cited: 383




List of shared articles



Times cited

Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
Dae-Seok Kim, Cristel V Camacho, W Lee Kraus. Exp Mol Med 2021
8

Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51.
Gwenola Manic, Martina Musella, Francesca Corradi, Antonella Sistigu, Sara Vitale, Sara Soliman Abdel Rehim, Luca Mattiello, Eva Malacaria, Claudia Galassi, Michele Signore,[...]. Cell Death Differ 2021
7

Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
M Chiappa, F Guffanti, F Bertoni, I Colombo, G Damia. Drug Resist Updat 2021
3

Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies.
Colin Stok, Yannick P Kok, Nathalie van den Tempel, Marcel A T M van Vugt. Nucleic Acids Res 2021
1

CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer.
Laia Castells-Roca, Eudald Tejero, Benjamín Rodríguez-Santiago, Jordi Surrallés. Cancers (Basel) 2021
2

Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance.
Christina Andronikou, Sven Rottenberg. Trends Mol Med 2021
2

Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.
Ke Cong, Min Peng, Arne Nedergaard Kousholt, Wei Ting C Lee, Silviana Lee, Sumeet Nayak, John Krais, Pamela S VanderVere-Carozza, Katherine S Pawelczak, Jennifer Calvo,[...]. Mol Cell 2021
6

Understanding and overcoming resistance to PARP inhibitors in cancer therapy.
Mariana Paes Dias, Sarah C Moser, Shridar Ganesan, Jos Jonkers. Nat Rev Clin Oncol 2021
3


Tackling PARP inhibitor resistance.
Kasper Fugger, Graeme Hewitt, Stephen C West, Simon J Boulton. Trends Cancer 2021
0

Determinants of Homologous Recombination Deficiency in Pancreatic Cancer.
Max M Wattenberg, Kim A Reiss. Cancers (Basel) 2021
0

Targeting DNA repair in cancer: current state and novel approaches.
Apostolos Klinakis, Dimitris Karagiannis, Theodoros Rampias. Cell Mol Life Sci 2020
18

53BP1: a DSB escort.
Zachary Mirman, Titia de Lange. Genes Dev 2020
55

Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
Feiyue Zheng, Yi Zhang, Shuang Chen, Xiang Weng, Yuefeng Rao, Hongmei Fang. Biomed Pharmacother 2020
17


The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.
Madalena Tarsounas, Patrick Sung. Nat Rev Mol Cell Biol 2020
49